

## Results of General Meeting

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, PYC Therapeutics Limited (the 'Company') advises that the resolutions contained in the Notice of Meeting dated 2 June 2023 and considered at today's General Meeting of Shareholders were all passed by the required majority following a poll conducted at the meeting. The proxies received in respect of each resolution are set in the attached proxy summary.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

For further information, please contact:

**Kevin Hart**

**Company Secretary**

+61 8 9316 9100

[info@pyctx.com](mailto:info@pyctx.com)

### About PYC Therapeutics

PYC Therapeutics (ASX:PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**<sup>1</sup>.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials and is now progressing multiple 'fast-follower' programs into the clinic. For more information, visit [pyctx.com](http://pyctx.com), or follow us on [LinkedIn](#). For more information, visit [pyctx.com](http://pyctx.com), or follow us on [LinkedIn](#) and [Twitter](#).

### CONTACTS:

#### INVESTORS

[info@pyctx.com](mailto:info@pyctx.com)

#### MEDIA

[info@pyctx.com](mailto:info@pyctx.com)

1. Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank  
<https://doi.org/10.1101/2020.11.02.2022232>

## Results of meeting

Name of entity

PYC THERAPEUTICS LIMITED

ABN/ACN/ARSN/ARBN

098 391 961

Date of meeting

5 JULY 2023

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolutions voted on at the meeting					If decided by poll					Proxies received			
No	Resolution Short description	Result	Voting method	If s250U applies	Voted for		Voted against		Abstained	For	Against	Abstain	Discretion
					Number	%	Number	%	Number	Number	Number	Number	Number
1	Ratification of prior Share issue under Placement (LR7.4)	Passed	Poll	n/a	671,137,778	99.81	1,250,000	0.19	5,020,000	665,161,598	1,250,000	5,020,000	90,308
2	Approval of Director Alan Tribe's participation in Placement (LR 10.11)	Passed	Poll	n/a	807,709,565	99.85	1,250,500	0.15	454,000	801,733,385	1,250,000	454,000	90,308
3	Approval of Director Rohan Hockings participation in Placement (LR 10.11)	Passed	Poll	n/a	807,709,565	99.85	1,250,500	0.15	454,000	801,733,385	1,250,500	454,000	90,308
4	Approval to issue Non-Director Tranche 2 Shares (LR7.1)	Passed	Poll	n/a	804,562,082	99.41	4,811,983	0.59	40,000	773,758,902	4,811,983	40,000	24,917,308